Is Coherus Oncology, Inc. overvalued?

Coherus Oncology, Inc. (CHRS) — key valuation metrics and fundamentals.

No verdict

Price

$1.20

Fair value

—

Current P/E

—

Normal P/E

9.4

Market cap

$185.4M

Dividend yield

0.0%

Return on equity

-181.7%

Sector

Healthcare

Fair value compares CHRS's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 12 Aug 2026.

Related stocks